Prior publications have suggested that RB1 + TP53 alterations are effective biomarkers for subclassification of LCNEC and may guide precise adjuvant chemotherapy for different subgroup patients [15–17]. The gene discussed is RB1; the disease is large cell neuroendocrine carcinoma.